These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 2053130)

  • 21. Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule.
    Guo XD; Harold N; Saif MW; Schuler B; Szabo E; Hamilton JM; Monahan BP; Quinn MG; Cliatt J; Nguyen D; Grollman F; Thomas RR; McQuigan EA; Wilson R; Takimoto CH; Grem JL
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):79-85. PubMed ID: 12707718
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of incadronate, a new bisphosphonate, in healthy volunteers and patients with malignancy-associated hypercalcemia.
    Usui T; Oiso Y; Tomita A; Ogata E; Uchida T; Ikeda K; Watanabe T; Higuchi S
    Int J Clin Pharmacol Ther; 1997 Jun; 35(6):239-44. PubMed ID: 9208339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: a cancer research campaign phase I/II committee study.
    Porter D; Boddy A; Thomas H; Lind M; Newell D; Calvert AH; Robson L; Brampton M; Abrahamsen D; Winograd B
    Semin Oncol; 1996 Dec; 23(6 Suppl 13):34-44. PubMed ID: 8996574
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of fluorouracil in humans.
    MacMillan WE; Wolberg WH; Welling PG
    Cancer Res; 1978 Oct; 38(10):3479-82. PubMed ID: 688233
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New limited sampling strategy for determining 5-fluorouracil area under the concentration-time curve after rapid intravenous bolus.
    Gusella M; Ferrazzi E; Ferrari M; Padrini R
    Ther Drug Monit; 2002 Jun; 24(3):425-31. PubMed ID: 12021636
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral 5-fluorouracil in psoriasis: pharmacokinetic-pharmacodynamic relationships.
    Abernethy DR; Alper JC; Wiemann MC; McDonald CJ; Calabresi P
    Pharmacology; 1989; 39(2):78-88. PubMed ID: 2798554
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disposition of 5-fluorouracil after intravenous bolus doses of a commercial formulation to cancer patients.
    Sitar DS; Shaw DH; Thirlwell MP; Ruedy JR
    Cancer Res; 1977 Nov; 37(11):3981-4. PubMed ID: 908036
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relative importance of dose, body surface area, sex, and age for 5-fluorouracil clearance.
    Port RE; Daniel B; Ding RW; Herrmann R
    Oncology; 1991; 48(4):277-81. PubMed ID: 1891168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of American ginseng on pharmacokinetics of 5-fluorouracil in rats.
    He YS; Sun W; Wang CZ; Qi LW; Yang J; Li P; Wen XD; Yuan CS
    Biomed Chromatogr; 2015 May; 29(5):762-7. PubMed ID: 25339249
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation between pharmacokinetic parameters of 5-fluorouracil and related metabolites and adverse reactions in East-Asian patients with advanced colorectal cancer.
    Tong Z; Cheng M; Yu Y; Yu J; Yin Y; Liu J; Zhang S; Jiang S; Dong M
    Cancer Chemother Pharmacol; 2022 Mar; 89(3):323-330. PubMed ID: 35067736
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Local pelvic irradiation modulates Pharmacokinetics of 5-Fluorouracil in the plasma but not in the Lymphatic System.
    Hsieh CH; Hou ML; Wang LY; Tai HC; Tsai TH; Chen YJ
    BMC Cancer; 2015 Apr; 15():316. PubMed ID: 25928348
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Salivary passage of 5-fluorouracil during continuous infusion.
    Milano G; Thyss A; Santini J; Frenay M; Francois E; Schneider M; Demard F
    Cancer Chemother Pharmacol; 1989; 24(3):197-9. PubMed ID: 2736710
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Drug interactions between interferon alpha 2b and 5-fluorouracil during continuous intravenous 5FU infusion].
    Czejka M; Schüller J; Schernhammer E; Bandak S
    Pharmazie; 1995 Jun; 50(6):416-9. PubMed ID: 7651979
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical significance of monitoring serum levels of 5-fluorouracil by continuous infusion in patients with advanced colonic cancer.
    Yoshida T; Araki E; Iigo M; Fujii T; Yoshino M; Shimada Y; Saito D; Tajiri H; Yamaguchi H; Yoshida S
    Cancer Chemother Pharmacol; 1990; 26(5):352-4. PubMed ID: 2208577
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nonlinear pharmacokinetics for the elimination of 5-fluorouracil after intravenous administration in cancer patients.
    McDermott BJ; van den Berg HW; Murphy RF
    Cancer Chemother Pharmacol; 1982; 9(3):173-8. PubMed ID: 7160054
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic drug monitoring (TDM) of 5-fluorouracil (5-FU): new preanalytic aspects.
    Mindt S; Aida S; Merx K; Müller A; Gutting T; Hedtke M; Neumaier M; Hofheinz RD
    Clin Chem Lab Med; 2019 Jun; 57(7):1012-1016. PubMed ID: 30699067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma levels of 5-fluorouracil after oral and intravenous administration in cancer patients.
    Finch RE; Bending MR; Lant AF
    Br J Clin Pharmacol; 1979 Jun; 7(6):613-7. PubMed ID: 465283
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Measurement of 5-FU plasma levels in patients with advanced cancer: correct approach to practical procedures is essential.
    Blaschke M; Cameron S; Emami K; Blumberg J; Wegner U; Nischwitz M; Ramadori G
    Int J Clin Pharmacol Ther; 2011 Jan; 49(1):83-5. PubMed ID: 21176739
    [No Abstract]   [Full Text] [Related]  

  • 39. [Pharmacokinetics of 5-fluorouracil in erythrocytes following i.v. administration].
    Czejka M; Schüller J; Fogl U
    Arch Pharm (Weinheim); 1992 Feb; 325(2):73-5. PubMed ID: 1605719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of interferon-alpha-2b on the blood-plasma levels of intraarterial administered fluorouracil.
    Czejka MJ; Schuller J; Fogl U; Weiss C
    Pharmazie; 1991 Nov; 46(11):817-8. PubMed ID: 1811238
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.